Following his presentation at the EAACI annual meeting, we were delighted to talk with Prof. Dr. Philippe Gevaert (University of Ghent, Belgium) about targeted endotype therapeutics in severe airway disease.
1. What are the major unmet needs in the treatment of severe airway disease? (0:04)
2. Could you give is a brief overview of the role of endotypes in airway disease? (1:20)
3.What have been the most promising endotype-driven approaches to date? (3:10)
4.What other emerging therapeutic targets would you like to highlight? (4:25)
5. What are the major challenges to be overcome before endotype-driven therapies can be implemented in routine clinical practice? (6:26)
Speaker disclosure: Philippe Gevaert has served as a speaker and advisor for Ablynx, Argenx, Astra Zeneca, Sanofi, Novartis, Regeneron, Genentech, ALK and Stallergenes-Greer
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EAACI Digital Congress 2020.
Share this Video
Related Videos In Chronic Cough
Peter Dicpinigaitis, ERS 2021: Unmet Needs and Advances in Chronic Cough
TouchRESPIRATORY got the opportunity to catch up with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to learn more about the unmet needs in chronic cough and recent clinical advances. Questions What are the unmet needs in the treatment of patients with refractory or unexplained chronic cough (RCC or […]
Peter Dicpinigaitis, ERS 2021: Gefapixant for Chronic Cough
It was a pleasure to meet with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to discuss the findings from the COUGH-1 and COUGH-2 studies, investigating gefapixant for the treatment of patients with chronic cough. The abstract ‘Patient-reported chronic cough severity over 52 weeks in two phase 3 trials […]
Jacky Smith, ATS 2021: Findings from the COUGH-1 and COUGH-2 Study Data
We were delighted to talk with Professor Jacky Smith (School of Biological Sciences, The University of Manchester, Manchester, UK) around cough frequency with gefapixant in patients with chronic cough. The abstract ‘Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2).’ was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!